drugset
drugset / Trial / NCT03332836

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

NCT03332836 ↗

Phase 1 Terminated 21 enrolled Hanmi Pharmaceutical Company Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.

Timeline

Start
2017-10-25
Primary completion
2019-01-30
Completion
2020-09-30

Outcome

Outcome not reported

Stopped: “Sopnsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject HM12460A Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus